$1.95
1.04% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US0547544033
Symbol
AYTU

Aytu BioScience Inc Stock price

$1.95
+0.71 57.26% 1M
+0.45 30.00% 6M
+0.25 14.71% YTD
-0.98 33.45% 1Y
-292.05 99.34% 5Y
-364,798.05 100.00% 10Y
+1.63 509.38% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.02 1.04%
ISIN
US0547544033
Symbol
AYTU

Key metrics

Market capitalization $12.03m
Enterprise Value $15.28m
P/E (TTM) P/E ratio 10.26
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.22
P/S ratio (TTM) P/S ratio 0.17
P/B ratio (TTM) P/B ratio 0.34
Revenue growth (TTM) Revenue growth -26.17%
Revenue (TTM) Revenue $69.22m
EBIT (operating result TTM) EBIT $368.00k
Free Cash Flow (TTM) Free Cash Flow $-5.74m
Cash position $18.17m
EPS (TTM) EPS $0.19
P/E forward 2.95
P/S forward 0.17
EV/Sales forward 0.22
Short interest 9.73%
Show more

Is Aytu BioScience Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Aytu BioScience Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aytu BioScience Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aytu BioScience Inc:

Buy
100%

Financial data from Aytu BioScience Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
69 69
26% 26%
100%
- Direct Costs 22 22
33% 33%
31%
47 47
22% 22%
69%
- Selling and Administrative Expenses 41 41
22% 22%
59%
- Research and Development Expense 2.15 2.15
3% 3%
3%
4.43 4.43
37% 37%
6%
- Depreciation and Amortization 4.07 4.07
20% 20%
6%
EBIT (Operating Income) EBIT 0.37 0.37
81% 81%
1%
Net Profit 1.64 1.64
112% 112%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Aytu BioScience Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aytu BioScience Inc Stock News

Neutral
Accesswire
4 days ago
Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepine Capital Management, with participation from Aytu management and new institutional shareholders.
Neutral
Accesswire
7 days ago
Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common s...
Neutral
Accesswire
7 days ago
Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, the incidence of sexual side effects experienced with EXXUA was c...
More Aytu BioScience Inc News

Company Profile

Aytu BioScience, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Natesto, Tuzistram, ZolpiMist and MiOXSYS. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Head office United States
CEO Joshua Disbrow
Employees 102
Founded 2002
Website aytubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today